WO2025098417 - SULFONAMIDE COMPOUND AND USE THEREOF
National phase entry is expected:
Publication Number
WO/2025/098417
Publication Date
15.05.2025
International Application No.
PCT/CN2024/130365
International Filing Date
07.11.2024
Title **
[English]
SULFONAMIDE COMPOUND AND USE THEREOF
[French]
COMPOSÉ SULFONAMIDE ET SON UTILISATION
[Chinese]
磺酰胺类化合物及其应用
Applicants **
XAICURE PHARMACEUTICALS (SUZHOU) CO., LTD
Inventors
WANG, Nannan
HUANG, Rui
CHENG, Xi
CAO, Bin
QIN, Li
TIAN, Ye
Priority Data
PCT/CN2023/130539
08.11.2023
CN
PCT/CN2024/096711
31.05.2024
CN
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
CNIPA
* |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| Translation |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 2468 | |
| EPO | Filing, Examination, Granting | 16389 | |
| Japan | Filing, Examination, Granting | 2329 | |
| South Korea | Filing, Examination, Granting | 2475 | |
| USA | Filing, Examination, Granting | 5190 |
Total:
28,851
The term for entry into the National Phase has expired. This quotation is for informational purposes only
Contact Us
Abstract[English]
Provided in the present application is a compound represented by formula (I), or an enantiomer, a diastereoisomer, a racemate, a tautomer, a stereoisomer, a geometric isomer, a nitrogen oxide, a metabolite or a pharmaceutically acceptable salt, an ester, a solvate, a hydrate, an isotope-labeled compound or a prodrug thereof. The compound represented by formula (I) of the present application has a relatively ideal inhibitory activity with regard to KAT6A and/or KAT6B.[French]
La présente demande concerne un composé représenté par la formule (I), ou un énantiomère, un diastéréoisomère, un racémate, un tautomère, un stéréoisomère, un isomère géométrique, un oxyde d'azote, un métabolite ou un sel pharmaceutiquement acceptable, un ester, un solvate, un hydrate, un composé marqué par un isotope ou un promédicament de celui-ci. Le composé représenté par la formule (I) selon la présente demande a une activité inhibitrice relativement idéale pour KAT6A et/ou KAT6B.[Chinese]
本申请提供一种式（I）所示的化合物，或其对映异构体、非对映异构体、消旋体、互变异构体、立体异构体、几何异构体、氮氧化物、代谢产物或其药学上可接受的盐、酯、溶剂化物、水合物、同位素标记化合物或前药。本申请式（I）所示化合物对KAT6A和/或KAT6B具有较理想的抑制活性。